MCRB Seres Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1609809 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY505.4%
TTM net income YoY-970.5%
TTM EPS YoY-1,766.7%
Revenue 3-yr CAGR-74.4%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-3,656.9%
Net margin-2,209.6%
FCF margin-3,010.4%
EBITDA margin-3,521.1%
Returns
ROE-144.3%
ROA-44.9%
ROIC (approx.)—
Asset turnover0.02x
Leverage & solvency
Liabilities / assets67.6%
Debt / equity0.00x
Current ratio1.65x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.36x
Accruals ratio16.2%
Payout ratio—
Capex / revenue1.4%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $593,000 | $736,000 | $358,000 | $438,000 | $351,000 | $0 | $0 | $0 |
| R&D expense | $5.59M | $9.14M | $13.20M | $11.68M | $12.62M | $12.94M | $11.82M | $12.84M |
| SG&A expense | $5.45M | $7.06M | $8.07M | $7.54M | $9.48M | $10.25M | $11.89M | $12.46M |
| Operating income | -$16.15M | -$21.27M | -$20.91M | -$19.38M | -$22.48M | -$24.88M | -$27.24M | -$28.84M |
| Interest expense | — | — | — | — | — | $0 | $0 | $0 |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$16.29M | $4.58M | -$19.91M | -$15.34M | $8.20M | -$19.86M | $32.68M | -$15.64M |
| EBITDA | -$15.67M | -$20.60M | -$20.13M | -$18.42M | -$21.43M | -$23.82M | -$26.16M | -$27.75M |
| EPS (basic) | -1.63 | 0.47 | -2.08 | — | 0.94 | -2.27 | 3.76 | — |
| EPS (diluted) | -1.63 | 0.47 | -2.08 | — | 0.94 | -2.27 | 3.75 | — |
| Weighted avg. shares (diluted) | 9.98M | 9.75M | 9.58M | — | 8.77M | 8.74M | 8.71M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $17.53M | $15.59M | $29.83M | $45.77M | $56.31M | $54.05M | $67.52M | $39.46M |
| Receivables | $183,000 | $274,000 | $233,000 | $157,000 | $351,000 | — | — | $0 |
| Current assets | $34.42M | $42.35M | $31.84M | $49.38M | $51.53M | $48.69M | $66.08M | $38.67M |
| PP&E, net | $3.00M | $5.80M | $6.85M | $7.63M | $8.58M | $9.62M | $10.55M | $11.53M |
| Total assets | $65.89M | $101.59M | $117.62M | $138.19M | $143.47M | $143.80M | $164.18M | $139.81M |
| Current liabilities | $20.89M | $20.03M | $19.34M | $19.32M | $22.43M | $30.94M | $31.32M | $41.22M |
| Total liabilities | $44.53M | $67.05M | $91.12M | $93.97M | $99.78M | $110.85M | $113.72M | $126.03M |
| Shareholders' equity | $21.36M | $34.53M | $26.50M | $44.22M | $43.70M | $32.95M | $50.47M | $13.78M |
| Shares outstanding | 10.05M | 9.83M | 9.59M | 9.56M | 8.76M | 8.75M | 8.73M | 8.65M |
| Cash flow statement | ||||||||
| Operating cash flow | -$10.48M | -$22.39M | -$16.36M | -$14.71M | $2.21M | -$13.29M | $26.91M | -$38.88M |
| Capital expenditure | $0 | $0 | $0 | $29,000 | $8,000 | $181,000 | $34,000 | $90,000 |
| Free cash flow | -$10.48M | -$22.39M | -$16.36M | -$14.74M | $2.20M | -$13.47M | $26.88M | -$38.97M |
| Investing cash flow | $12.55M | $14,000 | $0 | $181,000 | -$8,000 | -$181,000 | -$34,000 | -$90,000 |
| Financing cash flow | $752,000 | $1.72M | $428,000 | $12.66M | $61,000 | $0 | $1.18M | $1.74M |
| Depreciation & amortization | $481,000 | $670,000 | $781,000 | $954,000 | $1.04M | $1.06M | $1.08M | $1.08M |
| Stock-based compensation | $1.86M | $1.74M | $1.77M | $3.20M | $2.48M | $2.34M | $2.82M | $3.77M |
Free plan shows the latest 8 periods; Pro shows all 51 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.